vs
Hilton Grand Vacations Inc.（HGV）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Hilton Grand Vacations Inc.的季度营收约是Revvity的1.5倍（$1.2B vs $772.1M），Revvity净利率更高（12.7% vs 4.0%，领先8.7%），Revvity同比增速更快（5.9% vs 3.7%），Revvity自由现金流更多（$161.8M vs $147.0M），过去两年Revvity的营收复合增速更高（9.0% vs 7.4%）
希尔顿度假大酒店公司（Hilton Grand Vacations Inc.）总部位于美国佛罗里达州奥兰多，是一家跨国企业。该公司通过与希尔顿全球的独家授权协议，运营管理希尔顿旗下的分时度假和度假所有权品牌。其原为希尔顿全球的全资子公司，2017年分拆为独立上市公司。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HGV vs RVTY — 直观对比
营收规模更大
HGV
是对方的1.5倍
$772.1M
营收增速更快
RVTY
高出2.1%
3.7%
净利率更高
RVTY
高出8.7%
4.0%
自由现金流更多
RVTY
多$14.8M
$147.0M
两年增速更快
RVTY
近两年复合增速
7.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $48.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 7.8% | 14.5% |
| 净利率 | 4.0% | 12.7% |
| 营收同比 | 3.7% | 5.9% |
| 净利润同比 | 140.0% | 3.9% |
| 每股收益（稀释后） | $0.53 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HGVRVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M | ||
| Q1 24 | $1.0B | $649.9M |
净利润HGVRVTY
| Q4 25 | $48.0M | $98.4M | ||
| Q3 25 | $25.0M | $46.7M | ||
| Q2 25 | $25.0M | $53.9M | ||
| Q1 25 | $-17.0M | $42.2M | ||
| Q4 24 | $20.0M | $94.6M | ||
| Q3 24 | $29.0M | $94.4M | ||
| Q2 24 | $2.0M | $55.4M | ||
| Q1 24 | $-4.0M | $26.0M |
毛利率HGVRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率HGVRVTY
| Q4 25 | 7.8% | 14.5% | ||
| Q3 25 | 3.9% | 11.7% | ||
| Q2 25 | 3.8% | 12.6% | ||
| Q1 25 | -0.6% | 10.9% | ||
| Q4 24 | 4.3% | 16.3% | ||
| Q3 24 | 7.9% | 14.3% | ||
| Q2 24 | 0.6% | 12.4% | ||
| Q1 24 | -1.3% | 6.8% |
净利率HGVRVTY
| Q4 25 | 4.0% | 12.7% | ||
| Q3 25 | 2.1% | 6.7% | ||
| Q2 25 | 2.2% | 7.5% | ||
| Q1 25 | -1.7% | 6.4% | ||
| Q4 24 | 1.7% | 13.0% | ||
| Q3 24 | 2.5% | 13.8% | ||
| Q2 24 | 0.2% | 8.0% | ||
| Q1 24 | -0.4% | 4.0% |
每股收益（稀释后）HGVRVTY
| Q4 25 | $0.53 | $0.86 | ||
| Q3 25 | $0.28 | $0.40 | ||
| Q2 25 | $0.25 | $0.46 | ||
| Q1 25 | $-0.17 | $0.35 | ||
| Q4 24 | $0.19 | $0.77 | ||
| Q3 24 | $0.28 | $0.77 | ||
| Q2 24 | $0.02 | $0.45 | ||
| Q1 24 | $-0.04 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $239.0M | $919.9M |
| 总债务越低越好 | $4.5B | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $11.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 3.53× | — |
8季度趋势，按日历期对齐
现金及短期投资HGVRVTY
| Q4 25 | $239.0M | $919.9M | ||
| Q3 25 | $215.0M | $931.4M | ||
| Q2 25 | $269.0M | $991.8M | ||
| Q1 25 | $259.0M | $1.1B | ||
| Q4 24 | $328.0M | $1.2B | ||
| Q3 24 | $297.0M | $1.2B | ||
| Q2 24 | $328.0M | $2.0B | ||
| Q1 24 | $355.0M | $1.7B |
总债务HGVRVTY
| Q4 25 | $4.5B | — | ||
| Q3 25 | $4.7B | — | ||
| Q2 25 | $4.6B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.6B | — | ||
| Q3 24 | $5.0B | — | ||
| Q2 24 | $4.9B | — | ||
| Q1 24 | $5.1B | — |
股东权益HGVRVTY
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.5B | $7.6B | ||
| Q1 25 | $1.6B | $7.6B | ||
| Q4 24 | $1.8B | $7.7B | ||
| Q3 24 | $1.8B | $7.9B | ||
| Q2 24 | $1.9B | $7.9B | ||
| Q1 24 | $2.0B | $7.8B |
总资产HGVRVTY
| Q4 25 | $11.5B | $12.2B | ||
| Q3 25 | $11.7B | $12.1B | ||
| Q2 25 | $11.7B | $12.4B | ||
| Q1 25 | $11.8B | $12.4B | ||
| Q4 24 | $11.4B | $12.4B | ||
| Q3 24 | $11.2B | $12.8B | ||
| Q2 24 | $11.5B | $13.4B | ||
| Q1 24 | $11.7B | $13.4B |
负债/权益比HGVRVTY
| Q4 25 | 3.53× | — | ||
| Q3 25 | 3.41× | — | ||
| Q2 25 | 3.07× | — | ||
| Q1 25 | 2.83× | — | ||
| Q4 24 | 2.63× | — | ||
| Q3 24 | 2.73× | — | ||
| Q2 24 | 2.55× | — | ||
| Q1 24 | 2.57× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $167.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $147.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 12.3% | 21.0% |
| 资本支出强度资本支出/营收 | 1.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.48× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $230.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HGVRVTY
| Q4 25 | $167.0M | $182.0M | ||
| Q3 25 | $34.0M | $138.5M | ||
| Q2 25 | $61.0M | $134.3M | ||
| Q1 25 | $38.0M | $128.2M | ||
| Q4 24 | $105.0M | $174.2M | ||
| Q3 24 | $91.0M | $147.9M | ||
| Q2 24 | $113.0M | $158.6M | ||
| Q1 24 | $0 | $147.6M |
自由现金流HGVRVTY
| Q4 25 | $147.0M | $161.8M | ||
| Q3 25 | $13.0M | $120.0M | ||
| Q2 25 | $46.0M | $115.5M | ||
| Q1 25 | $24.0M | $112.2M | ||
| Q4 24 | $90.0M | $149.8M | ||
| Q3 24 | $81.0M | $125.6M | ||
| Q2 24 | $106.0M | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率HGVRVTY
| Q4 25 | 12.3% | 21.0% | ||
| Q3 25 | 1.1% | 17.2% | ||
| Q2 25 | 4.0% | 16.0% | ||
| Q1 25 | 2.4% | 16.9% | ||
| Q4 24 | 7.8% | 20.5% | ||
| Q3 24 | 6.9% | 18.4% | ||
| Q2 24 | 9.6% | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度HGVRVTY
| Q4 25 | 1.7% | 2.6% | ||
| Q3 25 | 1.8% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 1.4% | 2.4% | ||
| Q4 24 | 1.3% | 3.4% | ||
| Q3 24 | 0.9% | 3.3% | ||
| Q2 24 | 0.6% | 3.2% | ||
| Q1 24 | 1.0% | 2.7% |
现金转化率HGVRVTY
| Q4 25 | 3.48× | 1.85× | ||
| Q3 25 | 1.36× | 2.97× | ||
| Q2 25 | 2.44× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 5.25× | 1.84× | ||
| Q3 24 | 3.14× | 1.57× | ||
| Q2 24 | 56.50× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HGV
| Sales Of Vacation Ownership Intervals Net | $492.0M | 41% |
| Fee For Services Commissions Package Sales And Other Fees | $169.0M | 14% |
| Cost Reimbursements | $141.0M | 12% |
| Resort Management | $118.0M | 10% |
| Other | $116.0M | 10% |
| Club Management | $101.0M | 8% |
| Related Party | $42.0M | 4% |
| Ancillary Services | $13.0M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
